AntiCD25hodot

AntiCD25hodot is a recombinant monoclonal antibody engineered for targeted binding to the CD25 subunit of the interleukin‑2 receptor (IL‑2Rα). The antibody component retains the antigen‑recognition properties of conventional anti‑CD25 targeting agents such as basiliximab or daclizumab, while the additional “hodot” moiety—a hydroxypropyl‑methylcellulose conjugate—provides a biodegradable, hydrophilic polymer coat. This hydrogel-like layer can modulate the immunogenic profile of the antibody and improve its pharmacokinetic properties by reducing rapid clearance and limiting off‑target interactions.

The recombinant construct is expressed in CHO‑K1 cells and purified by protein A affinity chromatography followed by size‑exclusion chromatography to ensure monomeric purity. The final product has a buffered aqueous formulation suitable for intravenous infusion. The polymer conjugation is achieved via a maleimide–thiol reaction, yielding a stable thioether linkage that preserves the antigen‑binding site. The “hodot” polymer’s pegylated segments can also serve as a platform for further drug conjugation, enabling the creation of antibody‑drug hybrids for targeted delivery of cytotoxic agents to activated T‑cells.

Preclinical studies in mouse models of graft‑versus‑host disease and autoimmune myocarditis have shown that AntiCD25hodot reduces the number of proliferating CD4+CD25+ regulatory T‑cells without causing widespread T‑cell depletion. Pharmacodynamic analysis indicates a half‑life of approximately 7–10 days, longer than unconjugated anti‑CD25 antibodies. The polymer coating was found to diminish the activation of innate immune cells, which in turn lowered the incidence of infusion‑related cytokine release.

Currently, the compound is under Phase I clinical evaluation for safety and tolerability in patients undergoing hematopoietic stem‑cell transplantation. Investigators are also studying its potential as a carrier for selective delivery of immunomodulatory cytokines to CD25‑expressing lymphocytes. Should further trials confirm its efficacy and safety, AntiCD25hodot could offer a novel therapeutic option in the management of transplant rejection and autoimmune disorders.